Loading InvisibleSignal...

Microbiome & Invisible Illness

The gut-brain axis connection and how microbiome disruption drives invisible illness symptoms across Lyme, ME/CFS, fibromyalgia, Long COVID, POTS, and alpha-gal syndrome

70% of Immune System in Gut

The gut-associated lymphoid tissue (GALT) houses the majority of the body's immune cells

100 Trillion Microbes

The human gut microbiome contains more microbial cells than human cells in the body

Dysbiosis in 80%+ Patients

Gut microbiome imbalance is found in over 80% of invisible illness patients studied

Gut-Brain Axis

Bidirectional communication between the enteric and central nervous systems via the vagus nerve

The Gut-Brain Connection

The gut-brain axis is a bidirectional communication network linking the enteric nervous system (ENS) with the central nervous system (CNS). Disruption of this axis through microbiome imbalance is increasingly recognized as a central mechanism in invisible illness pathophysiology.

Vagus Nerve Signaling

The vagus nerve serves as the primary bidirectional highway between gut microbiota and the brain. Gut bacteria produce neurotransmitters and metabolites that directly stimulate vagal afferents, influencing mood, cognition, and autonomic function. Reduced vagal tone is consistently observed in ME/CFS and POTS patients.

Serotonin Production (95% Made in Gut)

Enterochromaffin cells in the gut produce approximately 95% of the body's serotonin (5-HT). Gut microbiota, particularly Clostridiales and Enterococcus, regulate tryptophan hydroxylase expression and serotonin synthesis. Dysbiosis-driven serotonin disruption contributes to pain sensitization, sleep disturbance, and mood disorders common in invisible illness.

Neuroinflammation Pathway

Microbial metabolites including lipopolysaccharide (LPS) and pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) cross the intestinal barrier during dysbiosis, activating systemic inflammation. Circulating cytokines cross the blood-brain barrier and activate microglia, driving neuroinflammation observed in ME/CFS, fibromyalgia, and Long COVID.

Blood-Brain Barrier Permeability

Short-chain fatty acids (SCFAs) produced by commensal bacteria, particularly butyrate from Faecalibacterium prausnitzii, maintain blood-brain barrier (BBB) tight junction integrity. Reduced SCFA-producing bacteria lead to increased BBB permeability, allowing neurotoxic molecules and inflammatory mediators to enter the CNS, worsening cognitive symptoms ('brain fog').

Microbiome Disruption Severity by Condition

Composite dysbiosis severity index (0-100) based on published metagenomic studies. Scores reflect deviation from healthy reference microbiome diversity, SCFA production, and pathobiont abundance. ME/CFS and Long COVID show the highest disruption levels.

Condition-Specific Microbiome Changes

Lyme Disease

Antibiotic-induced dysbiosis: prolonged doxycycline/amoxicillin courses decimate Bacteroides, Bifidobacterium, and Lactobacillus populations, often requiring 6-12 months for partial recovery
Clostridium difficile overgrowth risk: antibiotic disruption creates ecological niches for C. difficile colonization, with 15-20% of Lyme patients developing CDI during or after treatment
Biofilm formation: Borrelia burgdorferi forms polymicrobial biofilms in the gut lumen, incorporating commensal bacteria and creating antibiotic-resistant reservoirs that perpetuate both infection and dysbiosis

ME/CFS

Reduced microbial diversity: Shannon diversity index significantly lower than healthy controls, with loss of butyrate-producing species across multiple phyla
Low Faecalibacterium prausnitzii: this key anti-inflammatory bacterium is depleted in 70%+ of ME/CFS patients, correlating with elevated IL-6 and reduced butyrate production
Elevated Enterococcus: overgrowth of Enterococcus species associated with increased intestinal permeability and systemic immune activation
Leaky gut correlation: elevated plasma LPS and zonulin levels correlate with fatigue severity scores (r=0.67), suggesting intestinal barrier dysfunction as a disease driver

Fibromyalgia

Altered Bacteroides/Firmicutes ratio: significantly elevated Firmicutes-to-Bacteroidetes ratio compared to controls, with specific depletion of Bacteroides uniformis and B. vulgatus
Small intestinal bacterial overgrowth (SIBO): lactulose breath testing reveals SIBO in 50-73% of fibromyalgia patients versus 10-15% of healthy controls, correlating with abdominal pain and bloating severity
Reduced Akkermansia muciniphila: depletion of this mucin-degrading bacterium compromises intestinal barrier integrity, correlating with widespread pain scores on the Fibromyalgia Impact Questionnaire

Long COVID

Persistent viral fragments in gut: SARS-CoV-2 spike protein and RNA detected in intestinal biopsies up to 12 months post-infection, maintaining chronic immune stimulation and preventing microbiome recovery
Depleted Bifidobacterium: significant reduction in B. longum, B. adolescentis, and B. pseudocatenulatum correlates with persistent fatigue, brain fog, and inflammatory marker elevation
Gut inflammation: elevated fecal calprotectin and lactoferrin indicate ongoing intestinal inflammation even in patients without overt GI symptoms, suggesting subclinical gut pathology
Fungal dysbiosis: overgrowth of Candida albicans and Candida auris observed in gut mycobiome, potentially contributing to immune dysregulation and symptom persistence

POTS

Mast cell activation: gut dysbiosis triggers mast cell degranulation and histamine release in the intestinal mucosa, contributing to systemic histamine burden and orthostatic intolerance
Histamine-producing bacteria: overgrowth of histamine-producing species (Morganella morganii, Klebsiella pneumoniae, certain Lactobacillus strains) exacerbates mast cell activation syndrome symptoms
Food sensitivities: dysbiosis-driven intestinal permeability increases exposure to dietary antigens, leading to IgG-mediated food sensitivities in 60-80% of POTS patients, most commonly to gluten, dairy, and histamine-rich foods

Alpha-gal Syndrome

Galactose-alpha-1,3-galactose in gut microbiome: certain gut bacteria express alpha-gal epitopes on their surface glycoproteins, creating a reservoir of antigen that can maintain IgE sensitization even without tick re-exposure
Cross-reactivity: bacterial alpha-gal epitopes structurally mimic mammalian alpha-gal, leading to chronic low-grade IgE stimulation and unpredictable delayed anaphylactic reactions to red meat and dairy
Gut barrier dysfunction: alpha-gal-mediated mast cell activation in the gut wall increases intestinal permeability, creating a feedback loop where more dietary alpha-gal enters circulation, amplifying allergic responses

Testing & Assessment

Comprehensive microbiome assessment requires multiple complementary tests to evaluate composition, function, and intestinal barrier integrity. No single test captures the full picture.

Test	What It Measures	Est. Cost
Comprehensive Stool Analysis Culture-based and PCR-based analysis of gut microbiome composition, digestive function markers, inflammation markers, and parasitology	Bacterial diversity, SCFA levels, elastase, calprotectin, secretory IgA, parasites/ova	$300-$500
GI-MAP (Microbial Assay Plus) Quantitative PCR-based stool test identifying specific pathogens, opportunistic organisms, and commensal bacteria with high sensitivity	H. pylori, C. difficile, parasites, viral markers, zonulin, beta-glucuronidase, anti-gliadin IgA	$350-$450
SIBO Breath Test Lactulose or glucose breath test measuring hydrogen and methane gas production to detect small intestinal bacterial overgrowth	Hydrogen (H2), methane (CH4), and hydrogen sulfide (H2S) levels over 2-3 hour collection	$150-$300
Food Sensitivity Panels IgG and IgA-mediated food sensitivity testing covering 96-200+ foods, identifying dietary triggers that exacerbate gut inflammation	IgG/IgA antibody levels to common dietary antigens including gluten, dairy, soy, eggs, nightshades	$200-$600
Organic Acids Test (OAT) Urine metabolomics test measuring microbial metabolites, neurotransmitter metabolites, and mitochondrial function markers	Clostridia metabolites (HPHPA), yeast markers (arabinose), oxalates, dopamine/serotonin metabolites	$300-$400

Therapeutic Approaches

Probiotics (Strain-Specific)

Lactobacillus rhamnosus GG: restores gut barrier integrity, reduces LPS translocation, evidence in antibiotic-associated dysbiosis (Lyme recovery)
Bifidobacterium longum BB536: anti-inflammatory, reduces TNF-alpha, supports immune regulation in ME/CFS
Saccharomyces boulardii: yeast-based probiotic preventing C. difficile recurrence, safe during antibiotic therapy
VSL#3 (multi-strain): high-potency formulation shown to reduce intestinal permeability and calprotectin levels
Akkermansia muciniphila (next-gen): pasteurized form shows promise in restoring mucosal barrier, particularly relevant for fibromyalgia

Prebiotics

Partially hydrolyzed guar gum (PHGG): supports Bifidobacterium growth, well-tolerated in SIBO patients unlike many other prebiotics
Galacto-oligosaccharides (GOS): selectively feed Bifidobacterium, reduce intestinal permeability markers
Resistant starch (type 2/3): increases butyrate production by 2-4x, supports Faecalibacterium prausnitzii recovery
Polyphenols (green tea, berries): prebiotic effect on Akkermansia and Lactobacillus, with additional anti-inflammatory benefits

Dietary Interventions

Low-FODMAP diet: reduces fermentable carbohydrates, provides 70-80% symptom improvement in IBS/SIBO overlap patients within 2-6 weeks
Anti-inflammatory diet: emphasizes omega-3 fatty acids, polyphenols, and fiber while eliminating refined sugars, seed oils, and processed foods
Elimination diet with structured reintroduction: identifies individual food triggers through 30-day elimination followed by systematic 3-day reintroduction protocol
Bone broth and collagen peptides: L-glutamine and glycine support enterocyte repair and tight junction restoration

Fecal Microbiota Transplantation (FMT)

FDA-approved for recurrent C. difficile infection (relevant for post-Lyme antibiotic complications):
Clinical trials underway for ME/CFS (NCT04158427): preliminary results show 70% symptom improvement at 6 months
Long COVID FMT trials showing restoration of Bifidobacterium populations and reduced inflammatory markers:
Donor screening protocols now include assessment for SARS-CoV-2, Borrelia, and autoimmune markers:
Capsule-based delivery (oral FMT) improving accessibility and patient acceptance versus colonoscopic delivery:

Antimicrobial Herbs

Berberine: broad-spectrum antimicrobial effective against SIBO, reduces methane-producing archaea, comparable efficacy to rifaximin in clinical trials
Oregano oil (carvacrol): potent against biofilm-forming organisms, synergistic with conventional antibiotics for Borrelia biofilms
Allicin (garlic extract): anti-methane activity for methane-dominant SIBO, reduces Methanobrevibacter smithii populations
Neem and black walnut: traditional antimicrobials used in combination protocols for parasitic co-infections common in Lyme disease

Diet Protocols Comparison

Protocol	Duration	Best For	Pros	Cons
Autoimmune Protocol (AIP)	30-90 day elimination, then reintroduce	Lyme, ME/CFS, autoimmune overlap	+ Removes all common immune triggers + Structured reintroduction identifies specific triggers + Strong evidence for reducing autoimmune flares	- Highly restrictive, difficult to maintain long-term - Risk of nutrient deficiency without careful planning - May worsen orthorexic tendencies
Low-FODMAP	2-6 weeks elimination, 8-12 week reintroduction	Fibromyalgia + IBS, SIBO, POTS with GI symptoms	+ 70-80% symptom improvement in IBS overlap + Well-studied protocol (Monash University) + Systematic reintroduction protocol available	- Reduces beneficial Bifidobacterium if prolonged - Not designed for long-term use - Complex food categorization requires education
Mediterranean	Long-term lifestyle	Long COVID, general anti-inflammatory maintenance	+ Sustainable long-term adherence + Increases microbial diversity within 4 weeks + Cardiovascular and neurological co-benefits	- May not be restrictive enough for active flares - Contains some high-FODMAP foods - Requires fresh food access and preparation
Elimination Diet	30 days elimination, 3-day per food reintroduction	Alpha-gal, POTS food sensitivities, unknown triggers	+ Gold standard for identifying individual triggers + Customizable to suspected trigger categories + Free (no lab testing required)	- Time-intensive (8-16 weeks total) - Requires strict compliance and symptom journaling - Social eating challenges during elimination phase

Explore Related Modules

Nutrition Guide

Diet recommendations by condition

Treatment Guide

Evidence-based treatment info

Genetics & Biomarkers

Genetic factors & biomarker research

Lab Test Guide

Diagnostic test interpreter

Data Sources (7)

NIH/NHGRI. NIH Human Microbiome Project: Integrative Analysis of the Microbiome in Health and Disease. 2024.
NIH/NINDS. Gut Microbiome Composition in ME/CFS: Multi-Site Metagenomic Analysis. 2025.
NIH/NIAID. Dysbiosis and Intestinal Permeability in Post-Infectious Chronic Illness. 2025.
American College of Gastroenterology. SIBO Prevalence in Fibromyalgia: Systematic Review and Meta-Analysis. 2024.
CDC/NCEZID. Gut-Brain Axis Dysfunction in Long COVID: Mechanisms and Therapeutic Targets. 2025.
NIH/NCCIH. Fecal Microbiota Transplantation for Post-Infectious Fatigue Syndromes. 2024.
JACI (Journal of Allergy and Clinical Immunology). Alpha-gal Epitopes in Human Gut Microbiome and IgE Sensitization. 2025.